Literature DB >> 10733175

Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus.

T Lazzarotto1, S Varani, P Spezzacatena, L Gabrielli, P Pradelli, B Guerra, M P Landini.   

Abstract

In this study, we determined the avidity index (AI) of anticytomegalovirus (CMV) immunoglobulin G (IgG) and the anti-CMV immunoglobulin M (IgM) profile in 124 pregnant women, 87 of whom were considered at risk of transmitting CMV infection to their offspring and 37 of whom were at no risk. IgG avidity and blot for IgM were performed on two serum samples from each woman, at 6-18 weeks' gestation and at 20-23 weeks' gestation. Pregnancy outcomes were monitored. The results obtained showed that the determination of anti-CMV IgG avidity at 6-18 weeks' gestation can identify all women who would have an infected fetus/newborn (100% sensitivity), whereas IgM detected by blot had poorer results (69% sensitivity). Interestingly, at 20-23 weeks' gestation, the sensitivity of IgM detection by blot was higher than that obtained by avidity (75 % and 63%, respectively) and the combination of IgG avidity and IgM by blot yielded the best results (81% sensitivity).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733175     DOI: 10.1089/vim.2000.13.137

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  18 in total

1.  Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Cytomegalovirus infection in pregnancy: review of the literature.

Authors:  Silvia Bonalumi; Angelica Trapanese; Angelo Santamaria; Laura D'Emidio; Luisa Mobili
Journal:  J Prenat Med       Date:  2011-01

3.  National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity.

Authors:  Sheila C Dollard; Stephanie A S Staras; Minal M Amin; D Scott Schmid; Michael J Cannon
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

Review 4.  The "silent" global burden of congenital cytomegalovirus.

Authors:  Sheetal Manicklal; Vincent C Emery; Tiziana Lazzarotto; Suresh B Boppana; Ravindra K Gupta
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

5.  Overview of the diagnosis of cytomegalovirus infection.

Authors:  S A Ross; Z Novak; S Pati; S B Boppana
Journal:  Infect Disord Drug Targets       Date:  2011-10

6.  Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers.

Authors:  D Lang; R Vornhagen; M Rothe; W Hinderer; H H Sonneborn; B Plachter
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

7.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09

8.  Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Authors:  Mark R Schleiss; K Yeon Choi; Jodi Anderson; Janine Gessner Mash; Martine Wettendorff; Sally Mossman; Marc Van Damme
Journal:  Vaccine       Date:  2013-07-16       Impact factor: 3.641

Review 9.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

10.  Guinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission.

Authors:  Mark R Schleiss; Michael A McVoy
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.